A series of tweets earlier this year managed to push pharmaceutical companies including Pfizer Inc. to temporarily halt price increases. The main issue with the proposed rule is that a drug’s list or sticker price is very far from what many people or their health-care plans actually pay. In fact, the actual cost to patients with health insurance is usually even lower than the discounted price paid by health plans. This isn’t to say that list prices don’t matter at all or that they shouldn’t come down. It’s a safe bet that they will be emphasizing that the average cost to patients is usually below the list price.

Source: Washington Post October 15, 2018 22:07 UTC